Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Has Consensus Target Price of $41.25 According to Brokerages

Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $40.80.

Several equities research analysts have recently issued reports on PBLS shares. HC Wainwright assumed coverage on shares of Parabilis Medicines in a research note on Thursday, October 22nd. They issued a “buy” rating and a $40.00 price objective on the stock. Canaccord Genuity Group began coverage on Parabilis Medicines in a research report on Monday, November 9th. They issued a “buy” rating and a $39.00 price objective for the company. Finally, Weiss Ratings lowered Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, November 2nd.

Get Our Latest Analysis on PBLS

Institutional Investors Weigh In On Parabilis Medicines

A number of institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC grew its position in Parabilis Medicines by 95.5% in the third quarter. Parallel Advisors LLC now owns 1,075 shares of the company’s stock valued at $35,000 after acquiring an additional 525 shares during the period. Sterling Capital Management LLC acquired a new stake in shares of Parabilis Medicines in the 3rd quarter valued at $35,000. Russell Investments Group Ltd. bought a new stake in shares of Parabilis Medicines in the 3rd quarter worth about $96,000. Persistent Asset Partners Ltd bought a new stake in Parabilis Medicines during the second quarter worth about $113,000. Finally, Voya Investment Management LLC acquired a new stake in Parabilis Medicines during the 3rd quarter valued at $241,000.

Parabilis Medicines Price Performance

NASDAQ PBLS opened at $28.43 on Monday. The business’s 50-day simple moving average is $30.87. Parabilis Medicines has a twelve month low of $22.66 and a twelve month high of $42.49. The firm has a market cap of $3.51 billion and a PE ratio of -13.35.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.04. The business had revenue of $2.11 million during the quarter. As a group, sell-side analysts predict that Parabilis Medicines will post -2.60 earnings per share for the current fiscal year.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.

See Also

Analyst Recommendations for Parabilis Medicines (NASDAQ:PBLS)

Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.